AbbVie Inc. (ABBV) — closed signal from October 21, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 19, 2026 — -7.3% at the close.
Predicted vs. what happened
What happened
Reached 29% of the predicted growth at its peak, without hitting the target.
The thesis — published October 21, 2025
AbbVie's price looks beaten down in the short term, while overall investor mood remains upbeat. A recent study showed Rinvoq outperforming Humira, which supports the view that future sales can keep growing. The company's long history of paying and raising dividends adds a cushion. Short-term trend signs look weak, so we prefer a moderate position and look for the price to steady over the next 0-3 months.
Primary drivers
- Rinvoq topped Humira in a study, boosting confidence in future sales.
- Long record of rising dividends keeps many investors confident and engaged.
- Short-term signals look weak after a drop, so timing entries carefully matters.
- Strong overall mood, but keep position size modest to handle price swings.
How it played out
ABBV: target missed after a small early rise
Lyra published ABBV at $231.21 on 2025-10-21 with a short-term view for 12% growth. The thesis pointed to Rinvoq topping Humira in a study, a long record of rising dividends, weak short-term signals after a drop, and upbeat overall investor mood. It also called for moderate sizing over the next 0-3 months.
Inside the window, ABBV peaked at $239.29 on 2025-11-13, a 3.5% gain. It stayed below the $258.96 target. It never got there. By 2026-01-19, the stock ended at $214.35. The thesis only partially played out, because the price rose briefly but missed the target and finished below publication price.
What happened during the window
On 2025-10-31, AbbVie reported third-quarter results with $15.78 billion in revenue and adjusted earnings of $1.86 per share. On 2026-01-13, The Wall Street Journal reported that AbbVie struck a deal to invest $100 billion in U.S. operations and lower Medicaid prices.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.